NCT04475081View on ClinicalTrials.gov

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

May 15, 2022

Study Completion Date

May 15, 2022

Conditions
Sepsis Syndrome
Interventions
BIOLOGICAL

MMR vaccine

Merck MMR-II vaccine

Trial Locations (1)

70112

Clinical and Translational Research Center, New Orleans

All Listed Sponsors
collaborator

Parsemus Foundation

UNKNOWN

lead

Louisiana State University Health Sciences Center in New Orleans

OTHER

NCT04475081 - Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis | Biotech Hunter | Biotech Hunter